In today’s briefing:
- SPX Meeting Tactical Top Target
- EQD | SPX Vs NDX : Could CPI Spark a Reversal of Tech Performance Versus the Broader Market?
- First Solar Inc: Major Drivers
- Eli Lilly & Co: The Akouos Acquisition & Other Drivers
- Exxon Mobil Corp: Major Drivers
- AbbVie Inc: The DJS Antibodies Acquisition & Other Drivers
- Sporting Crypto – Nov 7th: Visa Celebrate World Cup 2022 with Masters of Movement
- Pfizer Inc (PFE.US) – What if Pfizer Loses the China Market in the Future?
- Pinterest Inc: New Marketing Campaign & Other Developments
- Shockwave Medical Inc (SWAV US): Continued Triple-Digit Sales Growth in Q3; 2022 Guidance Raised
SPX Meeting Tactical Top Target
- RTY long is falling short of our 1,850 PT. SPX met the 3,820/40 tactical top target outlined last week (rally from SPX 3,700). A C-wave decline is expected to 3,650.
- DXY near support while yield remains elevated is at odds. DXY rally due from 110/109.50 and if yield push higher will see equities buckle.
- NDX is the U/P short to add back to below 11,300. SPX long support zone rests at 3,650/20 with 3,600 the critical pivot to spur a fresh rise.
EQD | SPX Vs NDX : Could CPI Spark a Reversal of Tech Performance Versus the Broader Market?
- All eyes are on inflation data this week with CPI due out on Thursday
- Shorts in tech have been working but could be looking to take profits after big gains last week
- Use options for a cheap play on NDX outperformance over SPX
First Solar Inc: Major Drivers
- First Solar’s bull run was halted by a below par result in the last quarter as the company failed to meet Wall Street expectations with respect to revenues as well as earnings.
- The company’s manufacturing plants produced 2.4 gigawatts of modules in the third quarter and sold 2.8 gigawatts.
- Besides, their current fleet’s manufacturing performance metrics remain consistent, and plans for the third manufacturing plant in Ohio are still on track.
Eli Lilly & Co: The Akouos Acquisition & Other Drivers
- Eli Lilly’s stock has been on a roll off-late in a relatively challenging market environment and the company supported it with a solid result surpassing Wall Street expectations on all counts.
- They have continued to invest in expanding their manufacturing base to fulfill the rising demand for their products and prepare for upcoming launches.
- In this report, we have carried out a fundamental analysis of the historical financial statements of the company.
Exxon Mobil Corp: Major Drivers
- Like most other oil majors, Exxon Mobil too is trading close to its 52-week high.
- The company an delivered outstanding quarterly results driven by higher natural gas realizations, stronger refinery throughput, solid refining margins, and strict cost control.
- In the Permian Basin, Exxon increased output to almost 560,000 oil equivalent barrels per day, continuing their rapid expansion from the previous year.
AbbVie Inc: The DJS Antibodies Acquisition & Other Drivers
- AbbVie’s results for the past quarter were mixed and the company failed to meet Wall Street expectations with respect to its revenues but managed an earnings beat.
- The management also observed a persistently strong double-digit operational sales growth from several other significant products, including Botox Cosmetic, Vraylar, Venclexta, and Botox Therapeutic.
- This market growth is anticipated to primarily affect Juvederm and AbbVie’s body contouring portfolio products, which have higher consumer price points.
Sporting Crypto – Nov 7th: Visa Celebrate World Cup 2022 with Masters of Movement
- If you’re bored of reading FIFA-related stories – I’m sorry. The World Cup is on the horizon, after all!
- This project by the team over at Visa is probably the most interesting Web3 x World Cup project I’ve seen so far, however.
- Visa have created a generative art project where the art represents five iconic moments in World Cup history.
Pfizer Inc (PFE.US) – What if Pfizer Loses the China Market in the Future?
- If excluding the contribution from COVID-19 related products, Pfizer’s performance growth could have been quite pessimistic. In terms of BD, Pfizer is “a big buyer” but the return is questionable.
- We haven’t seen any blockbuster new products in Pfizer’s pipeline that can make up for the losses caused by VBP/NRDL negotiation in China. Price reduction seems the only way out.
- We cannot rule out that Pfizer may lose the China market in the event of further deterioration of Sino-US relations. This is a problem investors need to consider in advance.
Pinterest Inc: New Marketing Campaign & Other Developments
- Pinterest’s performance as a stock has been fairly decent in what can be termed as a tumultuous environment for the technology industry.
- The company’s global MAUs of 445 million were higher than in Q3 2021 because it largely overcame the pandemic’s difficulties and increased user engagement.
- During the quarter, they collaborated with Merlin, BMG, Warner Music Group, and Warner Chappell Music to enhance the music experience on Pinterest.
Shockwave Medical Inc (SWAV US): Continued Triple-Digit Sales Growth in Q3; 2022 Guidance Raised
- Shockwave Medical Inc (SWAV US) reported strong 3Q22 result, with revenue growing 102% y/y to 131.3 million, beating consensus by $7.5 million. EPS stood at $0.92, beating consensus by 35%.
- Revenue growth was driven by the launch of Shockwave C2, in the U.S. in February 2021, continued recovery from the pandemic impact, and increased adoption of Shockwave products.
- Shockwave now expects 2022 revenue of $483–488 million, representing 104–106% y/y growth. This compares to previous revenue guidance of $465–475 million and current consensus of $478.9 million.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars